UroGen Pharma Ltd (NASDAQ:URGN) price on current trading day, rose 0.66% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $12.29.
A look at the stock’s price movement, the close in the last trading session was $12.21, moving within a range at $12.25 and $12.68. The beta value (5-Year monthly) was 1.126. Turning to its 52-week performance, $20.70 and $10.60 were the 52-week high and 52-week low respectively. Overall, URGN moved 0.41% over the past month.
UroGen Pharma Ltd’s market cap currently stands at around $518.63 million, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 26.13M for the company’s revenue for the quarter, with a low and high estimate of 25.31M and 27.6M respectively. The average forecast suggests up to a 11.06% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 91.95M, representing a 11.17% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that URGN is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 5 recommend URGN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
URGN’s current price about 1.54% and 0.06% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 50.54, while 7-day volatility ratio is 4.47% and 5.01% in the 30-day chart. Further, UroGen Pharma Ltd (URGN) has a beta value of 1.07, and an average true range (ATR) of 0.63. Analysts have given the company’s stock an average 52-week price target of $40, forecast between a low of $22 and high of $60. Looking at the price targets, the low is -79.01% off current price level while to achieve the yearly target high, price needs to move -388.2%. Nonetheless, investors will most likely welcome a -225.47% jump to $40 which is the analysts’ median price.
If we refocus on UroGen Pharma Ltd (NASDAQ:URGN), historical trading data shows that trading volumes averaged 0.4 over the past 10 days and 572.26K over the past 3 months. The company’s latest data on shares outstanding shows there are 42.19 million shares.
The 13.47% of UroGen Pharma Ltd’s shares are in the hands of company insiders while institutional holders own 89.97% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.44 million on 2024-11-15, giving us a short ratio of 11.73. The data shows that as of 2024-11-15 short interest in UroGen Pharma Ltd (URGN) stood at 1563.0000999999997 of shares outstanding, with shares short falling to 6.49 million registered in 2024-10-15. Current price change has pushed the stock -18.07% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the URGN stock continues to rise going into the next quarter.
